

**JSP Pharmaceutical Manufacturing (Thailand)  
Public Co., Ltd. and its subsidiary**

Condensed interim financial statements  
for the three-month period ended  
31 March 2023  
and  
Independent auditor's review report

## **Independent Auditor’s Report on Review of Interim Financial Information**

### **To the Board of Directors of JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.**

I have reviewed the accompanying consolidated and separate statements of financial position of JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its subsidiary, and of JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd., respectively, as at 31 March 2023; the consolidated and separate statements of comprehensive income, changes in equity and cash flows for the three-month period ended 31 March 2023; and condensed notes (“interim financial information”). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34, “Interim Financial Reporting”. My responsibility is to express a conclusion on this interim financial information based on my review.

#### *Scope of Review*

I conducted my review in accordance with Thai Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

*Conclusion*

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34, “Interim Financial Reporting”.

(Kanokorn Phooriphanyawanit)  
Certified Public Accountant  
Registration No. 10512

KPMG Phoomchai Audit Ltd.  
Bangkok  
12 May 2023

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Statement of financial position

Assets	Note	Consolidated financial statements		Separate financial statements	
		31 March	31 December	31 March	31 December
		2023	2022	2023	2022
		(Unaudited)		(Unaudited)	
		<i>(in thousand Baht)</i>			
<b>Current assets</b>					
Cash and cash equivalents		115,079	95,800	113,250	91,336
Trade accounts receivable		64,609	71,648	64,609	71,648
Other receivables		32,652	26,195	31,068	25,661
Short-term loans to and interest receivable from a subsidiary	2	-	-	27,196	13,557
Inventories		100,027	99,121	100,027	99,121
Current contract cost assets	12	249	249	249	249
Other current financial asset	8	189,805	209,812	189,805	209,812
<b>Total current assets</b>		<b>502,421</b>	<b>502,825</b>	<b>526,204</b>	<b>511,384</b>
<b>Non-current assets</b>					
Other non-current financial asset		8,946	8,946	8,946	8,946
Investment in a subsidiary		-	-	30,000	30,000
Property, plant and equipment	3	756,341	669,080	705,853	633,316
Intangible assets		5,178	5,380	5,118	5,318
Deferred tax assets		19,716	20,062	19,151	19,779
Non-current contract cost assets	12	677	677	677	677
Other non-current assets		9,150	15,426	6,671	13,138
<b>Total non-current assets</b>		<b>800,008</b>	<b>719,571</b>	<b>776,416</b>	<b>711,174</b>
<b>Total assets</b>		<b>1,302,429</b>	<b>1,222,396</b>	<b>1,302,620</b>	<b>1,222,558</b>

The accompanying notes form an integral part of the interim financial statements.

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary**

**Statement of financial position**

	<i>Note</i>	<b>Consolidated financial statements</b>		<b>Separate financial statements</b>	
		31 March	31 December	31 March	31 December
		2023	2022	2023	2022
		(Unaudited)		(Unaudited)	
		<i>(in thousand Baht)</i>			
<b>Liabilities and equity</b>					
<i>Current liabilities</i>					
Trade accounts payable		41,747	46,161	41,741	46,161
Current contract liabilities		40,270	28,463	40,270	28,463
Other payables	2	29,476	24,375	27,413	23,404
Current portion of long-term loans					
from financial institutions	4	7,706	6,592	7,706	6,592
Current portion of lease liabilities	2, 4	6,706	6,454	6,706	6,454
<b>Total current liabilities</b>		<b>125,905</b>	<b>112,045</b>	<b>123,836</b>	<b>111,074</b>
<i>Non-current liabilities</i>					
Long-term loans from financial institutions	4	54,717	37,622	54,717	37,622
Lease liabilities	2, 4	107,527	109,426	107,527	109,426
Non-current contract liabilities		8,270	8,270	8,270	8,270
Non-current provisions for employee benefits		13,402	13,008	13,402	13,008
<b>Total non-current liabilities</b>		<b>183,916</b>	<b>168,326</b>	<b>183,916</b>	<b>168,326</b>
<b>Total liabilities</b>		<b>309,821</b>	<b>280,371</b>	<b>307,752</b>	<b>279,400</b>
<i>Equity</i>					
Share capital					
Authorised share capital		341,250	341,250	341,250	341,250
Issued and paid-up share capital		227,500	227,500	227,500	227,500
Share premium		733,463	733,463	733,463	733,463
Share subscriptions received in advance	5	48,724	-	48,724	-
Difference arising from common control transactions		(11,539)	(11,539)	(11,539)	(11,539)
Retained earnings (Deficit)					
Appropriated					
Legal reserve		3,862	3,862	3,862	3,862
Unappropriated		(9,402)	(11,261)	(7,142)	(10,128)
<b>Equity attributable to owners of the parent</b>		<b>992,608</b>	<b>942,025</b>	<b>994,868</b>	<b>943,158</b>
Non-controlling interests		-	-	-	-
<b>Total equity</b>		<b>992,608</b>	<b>942,025</b>	<b>994,868</b>	<b>943,158</b>
<b>Total liabilities and equity</b>		<b>1,302,429</b>	<b>1,222,396</b>	<b>1,302,620</b>	<b>1,222,558</b>

The accompanying notes form an integral part of the interim financial statements.

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Statement of comprehensive income (Unaudited)

	Note	Consolidated	Separate financial	
		financial statements	statements	
		Three-month period ended	Three-month period ended	
		31 March	31 March	
		2023	2023	2022
<i>(in thousand Baht)</i>				
<b>Revenue</b>				
Revenue from sale of goods		119,950	119,950	83,403
Other income		2,689	2,935	2,068
<b>Total revenue</b>		<b>122,639</b>	<b>122,885</b>	<b>85,471</b>
<b>Expenses</b>				
Cost of sale of goods		85,549	85,549	60,106
Distribution costs		9,756	9,756	22,373
Administrative expenses		23,275	22,113	15,981
<b>Total expenses</b>		<b>118,580</b>	<b>117,418</b>	<b>98,460</b>
<b>Profit (loss) from operating activities</b>		<b>4,059</b>	<b>5,467</b>	<b>(12,989)</b>
Finance costs		(1,921)	(1,921)	(1,791)
Gain (loss) on measurement of financial assets		(6)	(6)	357
Reversal of impairment loss				
determined in accordance with TFRS 9		74	74	509
<b>Profit (loss) before income tax expense</b>		<b>2,206</b>	<b>3,614</b>	<b>(13,914)</b>
Tax income (expense)		(347)	(628)	2,332
<b>Profit (loss) for the period</b>		<b>1,859</b>	<b>2,986</b>	<b>(11,582)</b>
<b>Other comprehensive income (expense) for the period, net of tax</b>		<b>-</b>	<b>-</b>	<b>-</b>
<b>Total comprehensive income (expense) for the period</b>		<b>1,859</b>	<b>2,986</b>	<b>(11,582)</b>
<b>Profit (loss) attributable to:</b>				
Owners of parent		1,859	2,986	(11,582)
Non-controlling interests		-	-	-
		<b>1,859</b>	<b>2,986</b>	<b>(11,582)</b>
<b>Total comprehensive income (expense) attributable to:</b>				
Owners of parent		1,859	2,986	(11,582)
Non-controlling interests		-	-	-
		<b>1,859</b>	<b>2,986</b>	<b>(11,582)</b>
<b>Basic earnings (loss) per share (in Baht)</b>	6	<b>0.004</b>	<b>0.01</b>	<b>(0.03)</b>
<b>Diluted earnings (loss) per share (in Baht)</b>	6	<b>0.003</b>	<b>0.01</b>	<b>(0.03)</b>

The accompanying notes form an integral part of the interim financial statements.



**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary**  
**Statement of changes in equity (Unaudited)**

	<b>Separate financial statements</b>						Total equity
	Issued and paid-up share capital	Share premium	Share subscriptions received in advance	Difference arising from common control transaction <i>(in thousand Baht)</i>	<u>Retained earnings (Deficit)</u>		
					Legal reserve	Unappropriated	
<b>Three-month period ended 31 March 2022</b>							
<b>Balance at 1 January 2022</b>	<b>227,500</b>	<b>733,463</b>	-	<b>(11,539)</b>	<b>3,862</b>	<b>13,140</b>	<b>966,426</b>
<b>Comprehensive income (expense) for the period</b>							
Loss	-	-	-	-	-	(11,582)	(11,582)
Other comprehensive income (expense)	-	-	-	-	-	-	-
<b>Total comprehensive income (expense) for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(11,582)</b>	<b>(11,582)</b>
<b>Balance at 31 March 2022</b>	<b>227,500</b>	<b>733,463</b>	-	<b>(11,539)</b>	<b>3,862</b>	<b>1,558</b>	<b>954,844</b>

The accompanying notes form an integral part of the interim financial statements.



**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary**

**Statement of changes in equity (Unaudited)**

	Note	Separate financial statements					Retained earnings (Deficit)		Total equity
		Issued and paid-up share capital	Share premium	Share subscriptions received in advance	Difference arising from common control transaction <i>(in thousand Baht)</i>	Legal reserve	Unappropriated		
<b>Three-month period ended 31 March 2023</b>									
<b>Balance at 1 January 2023</b>		<b>227,500</b>	<b>733,463</b>	<b>-</b>	<b>(11,539)</b>	<b>3,862</b>	<b>(10,128)</b>	<b>943,158</b>	
<b>Transactions with owners, recorded directly in equity</b>									
<i>Contributions by owners</i>									
Share subscriptions received in advance	5	-	-	48,724	-	-	-	48,724	
<b>Total contributions by owners</b>		<b>-</b>	<b>-</b>	<b>48,724</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>48,724</b>	
<b>Comprehensive income (expense) for the period</b>									
Profit		-	-	-	-	-	2,986	2,986	
Other comprehensive income (expense)		-	-	-	-	-	-	-	
<b>Total comprehensive income (expense) for the period</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,986</b>	<b>2,986</b>	
<b>Balance at 31 March 2023</b>		<b>227,500</b>	<b>733,463</b>	<b>48,724</b>	<b>(11,539)</b>	<b>3,862</b>	<b>(7,142)</b>	<b>994,868</b>	

The accompanying notes form an integral part of the interim financial statements.

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Statement of cash flows (Unaudited)

	<b>Consolidated financial statements</b>	<b>Separate financial statements</b>	
	Three-month period ended	Three-month period ended	
	31 March	31 March	
	2023	2023	2022
	<i>(in thousand Baht)</i>		
<b><i>Cash flows from operating activities</i></b>			
Profit (loss) for the period	1,859	2,986	(11,582)
<i>Adjustments to reconcile profit (loss) to cash receipts (payments)</i>			
Tax expense (income)	347	628	(2,332)
Finance costs	1,921	1,921	1,791
Depreciation and amortisation	9,075	8,898	5,301
Gain on disposal of other financial asset	(610)	(610)	(3)
(Gain) loss on fair value adjustment	6	6	(357)
Reversal of impairment loss in accordance with TFRS9	(74)	(74)	(509)
Employee benefits expense relating to defined benefit plans	394	394	318
Provision for loss on inventories devaluation	1,026	1,026	5,956
Gain on disposal of equipment	(22)	(22)	(794)
Interest income	-	(246)	(152)
	<u>13,922</u>	<u>14,907</u>	<u>(2,363)</u>
<b><i>Changes in operating assets and liabilities</i></b>			
Trade accounts receivable	7,113	7,113	(2,744)
Other receivables	(6,457)	(5,407)	280
Inventories	(1,932)	(1,932)	(10,190)
Other non-current assets	30	30	196
Trade accounts payable	(4,415)	(4,420)	(2,041)
Contract liabilities	11,807	11,807	(7,666)
Other payables	2,008	1,953	(14,199)
<b>Net cash generated from (used in) operating</b>	<b><u>22,076</u></b>	<b><u>24,051</u></b>	<b><u>(38,727)</u></b>
Taxes paid	-	-	-
<b>Net cash from (used in) operating activities</b>	<b><u>22,076</u></b>	<b><u>24,051</u></b>	<b><u>(38,727)</u></b>

The accompanying notes form an integral part of the interim financial statements.

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Statement of cash flows (Unaudited)

	<b>Consolidated financial statements</b>	<b>Separate financial statements</b>	
	Three-month period ended 31 March 2023	Three-month period ended 31 March 2023                      2022	
	<i>(in thousand Baht)</i>		
<b><i>Cash flows from investing activities</i></b>			
Proceeds from sale of equipment	28	28	814
Acquisition of property, plant and equipment	(86,734)	(72,681)	(37,166)
Acquisition of intangible assets	(73)	(73)	(577)
Payment of short-term loan to a subsidiary	-	(13,500)	-
Proceeds from sale of other financial asset	210,110	210,110	27,002
Payment of other financial asset	(189,500)	(189,500)	(190,000)
Interest received	-	107	-
<b>Net cash used in investing activities</b>	<b>(66,169)</b>	<b>(65,509)</b>	<b>(199,927)</b>
<b><i>Cash flows from financing activities</i></b>			
Cash received from advanced share subscriptions	48,725	48,725	-
Proceeds from bank overdrafts and short-term loans from financial institutions - net	-	-	2
Proceeds from long-term loans from financial institutions	19,900	19,900	-
Repayment of long-term loans from financial institutions	(1,735)	(1,735)	(21,894)
Payment of lease liabilities	(1,647)	(1,647)	(1,515)
Interest paid	(1,871)	(1,871)	(1,645)
<b>Net cash from (used in) financing activities</b>	<b>63,372</b>	<b>63,372</b>	<b>(25,052)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>19,279</b>	<b>21,914</b>	<b>(263,706)</b>
Cash and cash equivalents at 1 January	95,800	91,336	623,905
<b>Cash and cash equivalents at 31 March</b>	<b>115,079</b>	<b>113,250</b>	<b>360,199</b>
<b><i>Disclosure of additional cash flows information</i></b>			
<i>Property, plant and equipment acquired during the period were detailed as follows:</i>			
Total property, plant and equipment acquired during the period	96,068	81,169	27,800
Add Payment made to payables of plant and equipment at beginning of the period	953	423	4,149
Advance payments of plant and equipment at ending of the period	8,328	5,849	22,723
Less Payables of plant and equipment at ending of the period	(4,040)	(2,474)	(6,855)
Advance payments of plant and equipment at beginning of the period	(14,575)	(12,286)	(9,432)
Plant and equipment acquired from right-of-use assets	-	-	(1,219)
<b>Cash paid for acquisition of property, plant and equipment</b>	<b>86,734</b>	<b>72,681</b>	<b>37,166</b>

The accompanying notes form an integral part of the interim financial statements.

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.  
and its Subsidiary**

**Notes to the condensed interim financial statements**

**For the three-month period ended 31 March 2023 (Unaudited)**

<b>Note</b>	<b>Contents</b>
1	Basis of preparation of the interim financial statements
2	Related parties
3	Property, plant and equipment
4	Interest-bearing liabilities
5	Warrant
6	Earnings per share
7	Segment information and disaggregation of revenue
8	Financial instruments
9	Commitments with non-related parties
10	Contingent liabilities
11	Events after the reporting period
12	Reclassification of accounts

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Notes to the condensed interim financial statements

### For the three-month period ended 31 March 2023 (Unaudited)

These notes form an integral part of the interim financial statements.

The interim financial statements issued for Thai regulatory reporting purposes are prepared in the Thai language. These English language financial statements have been prepared from the Thai language statutory financial statements, and were approved and authorised for issue by the Board of Directors on 12 May 2023.

## 1 Basis of preparation of the interim financial statements

The condensed interim financial statements are presented in the same format as the annual financial statements together with notes to the interim financial statements on a condensed basis (“interim financial statements”) in accordance with Thai Accounting Standard (TAS) No. 34 *Interim Financial Reporting*, guidelines promulgated by the Federation of Accounting Professions and applicable rules and regulations of the Thai Securities and Exchange Commission. The interim financial statements focus on new activities, events and circumstances to avoid repetition of information previously reported in annual financial statements. Accordingly, these interim financial statements should be read in conjunction with the financial statements of the Company and its subsidiary for the year ended 31 December 2022.

In preparing these interim financial statements, judgements and estimates are made by management in applying the Group’s accounting policies. Actual results may differ from these estimates. The accounting policies, methods of computation and the key sources of estimation uncertainty were the same as those that described in the financial statements for the year ended 31 December 2022.

## 2 Related parties

Relationship with key management and other related parties of the Group and the Company have no material changes from financial statements for the year ended 31 December 2022.

<i>Significant transactions with related parties</i> <i>Three-month period ended 31 March</i>	<b>Consolidated</b>	<b>Separate</b>	
	<b>financial</b>	<b>financial statements</b>	
	<b>statements</b>	<b>2023</b>	<b>2022</b>
	<b>2023</b>	<b>(in thousand Baht)</b>	
<b>Ultimate parent company</b>			
Interest on lease liabilities	294	294	300
<b>Subsidiary</b>			
Interest income	-	246	-
<b>Key management personnel</b>			
Interest expense under lease liabilities	769	769	784
Key management personnel compensation			
Short-term employee benefit	4,796	4,796	5,615
Post-employment benefits	105	105	73
Total key management personnel compensation	<u>4,901</u>	<u>4,901</u>	<u>5,688</u>

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.**  
**and its Subsidiary**  
**Notes to the condensed interim financial statements**  
**For the three-month period ended 31 March 2023 (Unaudited)**

Balances as at 31 March 2023 and 31 December 2022 with related parties were as follows:

	<b>Consolidated financial statements</b>		<b>Separate financial statements</b>	
	31 March 2023	31 December 2022	31 March 2023	31 December 2022
	<i>(in thousand Baht)</i>			
<b>Short-term loans to</b>				
Subsidiary	-	-	27,000	13,500
<b>Total</b>	<b>-</b>	<b>-</b>	<b>27,000</b>	<b>13,500</b>
<b>Interest receivable</b>				
Subsidiary	-	-	196	57
<b>Total</b>	<b>-</b>	<b>-</b>	<b>196</b>	<b>57</b>
<b>Other payables</b>				
Key management personnel	400	1,556	400	1,556
<b>Total</b>	<b>400</b>	<b>1,556</b>	<b>400</b>	<b>1,556</b>
<b>Lease liabilities</b>				
Ultimate parent company	26,772	26,911	26,772	26,911
Key management personnel	69,927	70,290	69,927	70,290
<b>Total</b>	<b>96,699</b>	<b>97,201</b>	<b>96,699</b>	<b>97,201</b>

**Significant agreements with related parties**

During the three-month period ended 31 March 2023, the Company had no new significant agreements with the related parties.

**3 Property, plant and equipment**

Acquisitions, disposals and transfers of property, plant and equipment, excluding right-of-use assets during the three-month period ended 31 March 2023 were as follows:

	<b>Consolidated financial statements</b>		<b>Separate financial statements</b>	
	Acquisitions and transfers in - at cost	Disposals and transfers out - net book value	Acquisitions and transfers in - at cost	Disposals and transfers out - net book value
	<i>(in thousand Baht)</i>			
Land	40,327	-	40,327	-
Buildings and building improvements	56,020	-	56,020	-
Machinery and equipment	29,747	-	28,577	-
Furniture, fixtures and office equipment	4,070	(6)	3,752	(6)
Assets under construction and installation	27,543	(61,639)	14,132	(61,639)
<b>Total</b>	<b>157,707</b>	<b>(61,645)</b>	<b>142,808</b>	<b>(61,645)</b>

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.**  
**and its Subsidiary**  
**Notes to the condensed interim financial statements**  
**For the three-month period ended 31 March 2023 (Unaudited)**

Movement of right-of-use assets recognised as property, plant and equipment for the three-month period ended 31 March 2023 is as follows:

<i>Right-of-use assets</i>	<b>Consolidated and Separate financial statements</b>			
	Leasehold of land and buildings	Machinery and equipment <i>(in thousand Baht)</i>	Vehicles	Total
At 1 January 2023	102,960	5,884	3,684	112,528
Depreciation	(1,922)	(152)	(266)	(2,340)
<b>At 31 March 2023</b>	<b>101,038</b>	<b>5,732</b>	<b>3,418</b>	<b>110,188</b>

**4 Interest-bearing liabilities**

The periods to maturity of interest-bearing liabilities as at 31 March 2023 and 31 December 2022 were as follows:

	<b>Consolidated and Separate financial statements</b>					
	31 March 2023			31 December 2022		
	Current	Non-current	Total	Current	Non-current	Total
	<i>(in thousand Baht)</i>					
<b>Secured</b>						
Long-term loans from financial institutions (a)	7,706	54,717	62,423	6,592	37,622	44,214
Lease liabilities (b)	6,706	107,527	114,233	6,454	109,426	115,880
<b>Total interest-bearing liabilities</b>	<b>14,412</b>	<b>162,244</b>	<b>176,656</b>	<b>13,046</b>	<b>147,048</b>	<b>160,094</b>

The Group's and the Company's assets pledged as security for interest-bearing liabilities, excluding lease liabilities, as at 31 March 2023 and 31 December 2022 were as follows:

	<b>Consolidated financial statements</b>		<b>Separated financial statements</b>	
	31 March 2023	31 December 2022	31 March 2023	31 December 2022
	<i>(in thousand Baht)</i>			
Other non-current financial assets	8,946	8,946	8,946	8,946
Property, plant and equipment - at cost	151,534	70,087	129,104	70,087
<b>Total</b>	<b>160,480</b>	<b>79,033</b>	<b>138,050</b>	<b>79,033</b>

The periods to maturity of interest-bearing liabilities, excluding lease liabilities, as at 31 March 2023 and 31 December 2022 were as follows:

	<b>Consolidated and Separate financial statements</b>	
	31 March 2023	31 December 2022
	<i>(in thousand Baht)</i>	
Within one year	7,706	6,592
After one year but within five years	44,660	28,884
After five years	10,057	8,738
<b>Total</b>	<b>62,423</b>	<b>44,214</b>

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Notes to the condensed interim financial statements

### For the three-month period ended 31 March 2023 (Unaudited)

As at 31 March 2023, the Group and the Company had unutilised credit facilities amounting to Baht 101.5 million and Baht 101.5 million, respectively (31 December 2022: Baht 71.5 million and Baht 71.5 million, respectively).

As at 31 March 2023, the Group and Company have to comply with financial debt covenants on bank overdraft facilities amounting to Baht 45.0 million and Baht 30.0 million, respectively. (31 December 2022: nil). The covenants required the Company to maintain (1) debt-to-equity ratio not exceed than 1.0 time for the year 2022 onwards (2) debt service coverage ratio (DSCR) not less than 1.2 times for the year 2022 onwards and (3) interest-bearing debt to EBITDA not exceed than 4.5 times for the year 2022, not exceed than 3.0 times for the year 2023 and 2024 and not exceed than 2.0 times for the year 2025 onwards.

#### (a) Long-term loans from financial institutions

As at 31 March 2023, the Group and the Company had long-term loans from several financial institutions amounting to Baht 62.4 million and Baht 62.4 million, respectively (31 December 2022: Baht 44.2 million and Baht 44.2 million, respectively). These loans have various monthly repayment schedule for principal and interest up to 2030 as follows:

	Maturity of the last installment	Collaterals	Consolidated and Separate financial statements	
			31 March 2023	31 December 2022
			<i>(in thousand Baht)</i>	
Year 1: MLR-4.1%	2030	Land owned by the Company	24,385	25,086
Year 2-3: MLR-3.1%				
Year 4-5: MLR-2.1%				
Year 6 to maturity: MLR-1.6%				
Year 1-3: MLR-2.55%	2028	Land owned by the Company and a subsidiary	19,901	-
Year 4-maturity: MLR-2.3%				
Year 1-2: MLR-2.0%	2027	Key management personnel and Thai Credit Guarantee Corporation (TCG)	17,000	17,782
Year 3-maturity: MLR-1.0%				
Year 1-2: 2.0% Year 3-maturity: 7.0%	2026	Thai Credit Guarantee Corporation (TCG)	1,111	1,194
2.0% per annum	2023	Bank guarantee from a financial institution	26	152
		<b>Total</b>	<b>62,423</b>	<b>44,214</b>



# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Notes to the condensed interim financial statements

### For the three-month period ended 31 March 2023 (Unaudited)

As at 31 March 2023, the Company has to comply with financial debt covenants on long-term loans from financial institution amounting to Baht 20.0 million. (31 December 2022: nil) The covenants required the Company to maintain (1) debt-to-equity ratio not exceed than 1.0 time for the year 2022 onwards (2) debt service coverage ratio (DSCR) not less than 1.2 times for the year 2022 onwards and (3) interest-bearing debt to EBITDA not exceed than 4.5 times for the year 2022, not exceed than 3.0 times for the year 2023 and 2024 and not exceed than 2.0 times for the year 2025 onwards.

#### (b) Lease liabilities

The periods to maturity of lease liabilities were as follows:

	Consolidated and Separate financial statements					
	31 March 2023			31 December 2022		
	Lease payments over the remaining term of the lease liabilities	Interest	Carrying value of lease liabilities (in thousand Baht)	Lease payments over the remaining term of the lease liabilities	Interest	Carrying value of lease liabilities
Within one year	11,660	(4,954)	6,706	11,475	(5,021)	6,454
After one year but within five years	41,058	(16,827)	24,231	41,911	(17,135)	24,776
After five years	108,540	(25,244)	83,296	110,784	(26,134)	84,650
<b>Total</b>	<b>161,258</b>	<b>(47,025)</b>	<b>114,233</b>	<b>164,170</b>	<b>(48,290)</b>	<b>115,880</b>

#### Recognised in profit or loss

##### For the three-month period ended 31 March

	Consolidated and Separate financial statements 2023	Separate financial statements 2022
	(in thousand Baht)	
Interest on lease liabilities	1,265	1,101
Expenses relating to short-term leases or leases of low-value assets	46	315

Total cash outflow for leases presented in the consolidated and separate statement of cash flows for the three-month period ended 31 March 2023 were Baht 1.6 million and Baht 1.6 million, respectively. (2022: separate financial statements was Baht 1.5 million).

The Company entered into lease agreements with local companies and related parties to lease property, plant and equipment. Under the term of agreements, the Company had to comply with the conditions related to leased assets.

## 5 Warrant

On 16 August 2022, the Extraordinary General Meeting of Shareholders had resolutions approve the issue of warrant to purchase the newly issued ordinary shares of the Company (JP-W1, which subsequently change security symbol to JSP-W1 on 22 September 2022) not exceeding 227.5 million units, to be allotted to the existing shareholders of the Company pro rata to their respective shareholdings (Rights Offering) at the allotment ratio of every 2 existing ordinary shares for 1 unit of JSP-W1 warrant. The warrant had details as follow:

# JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary

## Notes to the condensed interim financial statements

### For the three-month period ended 31 March 2023 (Unaudited)

Description	Details
Grant date	31 August 2022
Exercise ratio	1 unit of warrant per 1 ordinary share, except there is a change according to the right adjustment conditions
Exercise price	Baht 2.50 per share, except there is a change according to the right adjustment conditions
Exercise period and proportion	The Warrant holders may exercise the rights under the warrants on the last Business Day of March and September throughout the Term of Warrants. The Warrant holders may exercise their rights for the first time on the last Business Day of March i.e. 31 March 2023 and the last time to exercise their rights is the date such that the Warrants have 2 years from the Warrant Issuance Date, which shall be 30 August 2024.

During the three-month period ended 31 March 2023, there were 19,489,800 units of JSP-W1 warrant exercised into 19,489,800 ordinary shares at exercise price of Baht 2.50. The Company has fully received cash for such capital increased and has registered the increase of share capital with the Ministry of Commerce on 12 April 2023 and recorded subscriptions received in advance from the exercise of warrants of Baht 48.72 million in shareholders' equity, under the caption of "Share subscriptions received in advance" in the statement of financial position. As at 31 March 2023, there were 208,008,998 unexercised warrants outstanding.

## 6 Earnings per share

	<b>Consolidated financial statements</b>	<b>Separate financial statements</b>	
	2023	2023	2022
	<i>(in thousand Baht/thousand shares)</i>		
<i>For the three-month period ended 31 March</i>			
<b>Profit (loss) for the period attributable to ordinary shareholders of the Company (basic and diluted)</b>	<b>1,859</b>	<b>2,986</b>	<b>(11,582)</b>
<i>Ordinary shares outstanding</i>			
Number of ordinary shares outstanding at 1 January	455,000	455,000	455,000
<b>Weighted average number of ordinary shares outstanding (basic)</b>	<b>455,000</b>	<b>455,000</b>	<b>455,000</b>
Effect of exercise of warrants	85,878	85,878	-
<b>Weighted average number of ordinary shares outstanding (diluted)</b>	<b>540,878</b>	<b>540,878</b>	<b>455,000</b>
<b>Earnings (losses) per share (basic) (in Baht)</b>	<b>0.004</b>	<b>0.01</b>	<b>(0.03)</b>
<b>Earnings (losses) per share (diluted) (in Baht)</b>	<b>0.003</b>	<b>0.01</b>	<b>(0.03)</b>

# **JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary**

## **Notes to the condensed interim financial statements**

**For the three-month period ended 31 March 2023 (Unaudited)**

### **7 Segment information and disaggregation of revenue**

Management determined that the Group and Company has two reportable segments which are the Group's strategic divisions for different products, and are managed separately because they require different technology and marketing strategies. The following summary describes the operations in each of the Group's reportable segments.

Segment 1      Manufacture and distribution of products under customer's brand name (OEM)

Segment 2      Manufacture and distribution of products under the Company's brand name (Own brands)

Other segments include revenue from sales of goods and service. None of these segments meets the quantitative thresholds for determining reportable segments in 2023 or 2022.

Each segment's performance is measured based on segment operating profit, as included in the internal management reports that are reviewed by the Group's CODM. Segment operating profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of segments.

The Group and Company's main revenue is derived from contracts with customers and recognised at a point in time.

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.  
and its Subsidiary**

**Notes to the condensed interim financial statements**

**For the three-month period ended 31 March 2023 (Unaudited)**

<i>For the three-month period ended 31 March</i>	<b>Consolidated financial statements</b>				<b>Total 2023</b>
	<b>Segment 1 2023</b>	<b>Segment 2 2023</b>	<b>Other segments 2023</b>		
			<i>(in thousand Baht)</i>		
Revenues from sales of goods	53,067	65,845	1,038		119,950
<b>Profit (loss) from operations</b>	<b>1,642</b>	<b>23,087</b>	<b>(84)</b>		<b>24,645</b>
Unallocated revenues					2,689
Unallocated expenses					(23,275)
Loss on measurement of financial assets					(6)
Reversal of impairment loss in accordance with TFRS9					74
Finance costs					(1,921)
<b>Profit before income tax expense</b>					<b>2,206</b>

<i>For the three-month period ended 31 March</i>	<b>Separate financial statements</b>						<b>Total</b>	
	<b>Segment 1</b>		<b>Segment 2</b>		<b>Other segments</b>		2023	2022
	2023	2022	2023	2022	2023	2022		
					<i>(in thousand Baht)</i>			
Revenues from sales of goods	53,067	49,140	65,845	31,440	1,038	2,823	119,950	83,403
<b>Profit (loss) from operations</b>	<b>1,642</b>	<b>4,236</b>	<b>23,087</b>	<b>(3,139)</b>	<b>(84)</b>	<b>(173)</b>	<b>24,645</b>	<b>924</b>
Unallocated revenues							2,935	2,068
Unallocated expenses							(22,113)	(15,981)
Gain (loss) on measurement of financial assets							(6)	357
Reversal of impairment loss in accordance with TFRS9							74	509
Finance costs							(1,921)	(1,791)
<b>Profit (loss) before income tax expense</b>							<b>3,614</b>	<b>(13,914)</b>

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.  
and its Subsidiary**

**Notes to the condensed interim financial statements**

**For the three-month period ended 31 March 2023 (Unaudited)**

**8 Financial instruments**

*Carrying amounts and fair values*

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities measured at amortised cost if the carrying amount is a reasonable approximation of fair value.

<b>Consolidated and Separate financial statements</b>								
<b>Carrying amount</b>			<b>Fair value</b>					
Hedging instruments	Financial instruments measured at FVTPL	Financial instruments measured at FVOCI	Total	Level 1	Level 2	Level 3	Total	
<i>(in thousand Baht)</i>								
<b>Financial assets</b>								
<b>At 31 March 2023</b>								
Investment in short-term structured note	-	189,806	-	189,806	-	189,806	-	189,806

<b>Consolidated and Separate financial statements</b>								
<b>Carrying amount</b>			<b>Fair value</b>					
Hedging instruments	Financial instruments measured at FVTPL	Financial instruments measured at FVOCI	Total	Level 1	Level 2	Level 3	Total	
<i>(in thousand Baht)</i>								
<b>Financial assets</b>								
<b>At 31 December 2022</b>								
Investment in short-term structured note	-	209,812	-	209,812	-	209,812	-	209,812

**JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd.  
and its Subsidiary**

**Notes to the condensed interim financial statements**

**For the three-month period ended 31 March 2023 (Unaudited)**

**9 Commitments with non-related parties**

	<b>Consolidated financial statements</b>		<b>Separate financial statements</b>	
	31 March 2023	31 December 2022	31 March 2023	31 December 2022
	<i>(in thousand Baht)</i>			
<b>Capital commitments</b>				
Building and building improvements	21,147	34,019	14,262	32,264
Furniture, fixtures and office equipment	-	229	-	229
<b>Total</b>	<b>21,147</b>	<b>34,248</b>	<b>14,262</b>	<b>32,493</b>
<b>Other commitments</b>				
Bank guarantees	<b>2,831</b>	<b>2,831</b>	<b>2,831</b>	<b>2,831</b>

As at 31 March 2023 and 31 December 2022, the Company had bank guarantees with a financial institution, issued to Provincial Electricity Authority to guarantee for electricity usage amounting to Baht 1.8 million, issued to Metropolitan Electricity Authority to guarantee for electricity usage amounting to Baht 0.6 million, issued to Safety, Health and Environmental At Work Fund for securing a borrowing amounting to Baht 0.4 million and issued to Mahidol University (Faculty of Dentistry) amounting to Baht 0.1 million.

**Significant agreement with non-related party**

On 28 February 2023, the Company entered into the Memorandum of Agreement with a customer to support sell of the certain product from 1 March 2023 to 31 December 2023. Under the term of the Memorandum of Agreement, the Company agrees to pay a consideration to the customer totalling Baht 33.3 million as per the term stipulated in the Memorandum of Agreement.

As at 31 March 2023, the Company recorded advance payment and accrued expenses relating to such agreement of Baht 10.0 million and Baht 6.7 million, respectively. The Company recorded consideration payable to a customer net from revenue from sales of goods for the three-month period ended 31 March 2023 of Baht 0.03 million.

**10 Contingent liabilities**

On 11 September 2019, the Company was accused in trademark infringement case with claim amounting to Baht 50.0 million. On 14 December 2021, the Central Intellectual Property and International Trade Court (“the Court”) dismissed the case. Later on 20 May 2022, the plaintiff appealed the case to the Specialised Court of Appeal. The judgement was read on 16 January 2023 by the Specialised Court of Appeal to dismiss the case.

However, the plaintiff appealed the case to extend period of petition filing to 12 May 2023 which was accepted by the Court. As such, it is not possible, at this stage, to identify whether any claims may be incurred at 31 March 2023. Therefore, the Company has not recorded liabilities from the cases as the management believed the Company did not commit such infringement.

# **JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. and its Subsidiary**

## **Notes to the condensed interim financial statements**

### **For the three-month period ended 31 March 2023 (Unaudited)**

#### **11 Events after the reporting date**

On 18 April 2023, the Annual General Meeting of Shareholders had a resolution to approve the Company to invest in ordinary shares of CDIP (Thailand) Public Co., Ltd. in the amount not exceeding 156.0 million shares; accounted for 65.0% of registered paid-up capital, with consideration not exceeding Baht 200.0 million from the Company's related parties.

On 12 May 2023, the Board of Directors, meeting had a resolution to approve the Company to invest in ordinary shares of Grace Water Med Company Limited in the amount not exceeding 21,118 shares, accounted for 52.8% of registered and paid-up capital, with consideration not exceeding Baht 43.9 million from the Company's non-related parties.

#### **12 Reclassification of accounts**

Certain accounts in the statement of financial position as at 31 December 2022 have been reclassified to conform to the presentation of the interim financial statements as at 31 March 2023. The reclassifications have been made because, in the opinion of management, the new classification is more appropriate to the Group's business.

	<b>Consolidated and Separate financial statements</b>		
	<b>2022</b>		
	<b>Before</b>		<b>After</b>
	<b>reclassification</b>	<b>Reclassification</b>	<b>reclassification</b>
		<i>(in thousand Baht)</i>	
<b><i>As at 31 December 2022</i></b>			
Current contract cost assets	717	(468)	249
Non-current contract cost assets	209	468	677
		<u>-</u>	